The ethics of paediatric anti-depressant use: Erring on the side of caution

Journal of Medical Ethics

Volumn 34, Issue 10, 2008, Pages 710-714

  Shearer, M C ^a,b   Bermingham, S L ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; CHILD; DEPRESSION; ETHICS; HUMAN; MEDICAL ETHICS; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SUICIDE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; ETHICS, MEDICAL; FLUOXETINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 56749104280     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2007.023119     Document Type: Review

References (56)

1. Ryan RD. Treatment of depression in children and adolescents. Lancet 2005;366:933-40.
2. Carlson GA. The challenge of diagnosing depression in childhood and adolescence. J Affect Disorders 2000;61(Suppl):3-8.
3. Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiat Serv 2000;51:627-33.
4. NHS National Institute for Health and Clinical Excellence (NICE). Depression in children and young people: identification and management in primary, community and secondary care. NICE Clinical Guideline 28. September 2005. http://www.nice.org.uk/CG028 (accessed 18 Jul 2008).
5. European Medicines Agency. European Medicines Agency adopts a positive opinion for the use of Prozac in the treatment of children and adolescents suffering from depression. Press Release 6 June 2006. http://www.emea.europa.eu/pdfs/human/press/pr/20255406en.pdf (accessed 18 Jul 2008).
6. Timimi S. Rethinking childhood depression. BMJ 2004;329:1394-6.
7. Hansard. Written answers, House of Commons, 19 July 2007, Column 536W.
8. Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 2004;89:1131-2.
9. Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879-83.
10. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA 2004;292:807-20.
11. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive-behavioural therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335:142-6.
12. Kozart M. Re:Re:Re: Fluoxetine for depressed adolescents: harms likely to exceed benefits. BMJ Rapid Responses 25 May 2007. http://www.bmj.com/cgi/eletters/330/7493/730-b (accessed 23 August 2007). LV CHECK AGAIN, not working
13. Jureidini JN. Study was not a trial of antidepressants. BMJ 2007;335:221.
14. Scharko AM. Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. J Am Acad Adolesc Psychiat 2004;43:1071-9.
15. Couzin J. Volatile chemistry: children and antidepressants. Science 2004;305:468-70.
16. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiat Neurosci 2003;28:331-7.
17. Leo J. The SSRI trials in children: disturbing implications for academic medicine. Ethical Hum Psychol Psychiat 2006;8:29-41.
18. Whittington CJ, Kendell T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
19. Check E. US antidepressants to carry suicide warnings. news@nature.com 18 October 2004. doi:10.1038/news041018-2.
20. Eli Lilly and Company Limited. Prozac 20mg hard capsules. Product information sheet PL 00006/0195, 21 August 2006. From MRHA 8 August, 2007.
21. Blakemore S-J, Choudhury S. Brain development during puberty: state of the science. Developmental Sci 2006;9:11-14.
22. Andersen SL, Navalta CP. Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 2004;22:423-40.
23. Ansorge MS, Zhou M, Lira A, et al. Early-life blockade of the 5HT transporter alters emotional behavior in adult mice. Science 2004;306:879-81.
24. LaRoche RB, Morgan RE. Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats. Neurotoxicol Teratol 2007;29:96-107.
25. Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsycopharmacology 2006;31:47-57.
26. Norrholm SD, Ouimet CC. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine formation in hippocampus. Brain Res 2000;883:205-15.
27. Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005;146:658-93.
28. Nilsson M, Joliat MJ, Miner CM, et al. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmaol 2000;14:412-17.
29. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002:156:696-701.
30. National Institute for Health and Clinical Excellence (NICE). Depression in children and young people: Understanding NICE guidance - information for children and young people with depression, their families and carers, and the public. Information about NICE Clinical Guideline 28. September 2005. http://www.nice.org.uk/guidance/index.jsp?action=byID&o= 10970 (accessed 18 Jul 2008).
31. Cheshire and Wirral Partnership NHS Trust. Fluoxetine: antidepressant medication for children and young people - Information for parents and carers. February 2006. Code: D-AD-06-014. Available from Cheshire and Wirral Partnership NHS Trust, Upton Lea, Countess of Chester Health Park, Liverpool Road, Chester CH2 1BQ.
32. Sparks JA, Duncan BL. The ethics and science of medicating children. Ethical Hum Psychol Psychiat 2004;6:34.
33. Fisher RL, Fisher S. Antidepressants for children. Is scientific support necessary? J Nerv Ment Dis 1996;184:99-102.
34. Leo J. The SSRI trials in children: disturbing implications for academic medicine. Ethical Hum Psychol Psychiat 2006;8:29-41.
35. Gazzaniga MS. The ethical brain: the science of our moral dilemmas. New York: Harper Perennial, 2005:XV.
36. Parker G. Is depression overdiagnosed? Yes. BMJ 2007;355:328.
37. Elliott C. Pursued by happiness and beaten senseless: Prozac and the American Dream. Hastings Cent Rep 2000;30:7-12.
38. Anon. How do we tackle the rise in the number of children on antidepressants? Independent 12 Aug 2007. http://news.independent.co.uk/ health/article2851984.ece (accessed 18 Jul 2008).
39. Lenzer J. US teenager's parents sue school over depression screening test. BMJ 2005;331:714.
40. Garber J, Horowitz JL. Depression in children. In: Gotlib IH, Hammen CL, eds. Handbook of depression. London: Guilford Press, 2002:539.
41. Hollon SD, Haman KL, Brown LL. Cognitive-behavioural treatment of depression. In: Gotlib IH, Hammen CL, eds. Handbook of depression. London: Guilford Press, 2002.
42. Diller L. Antidepressants and children's depression. Am J Psychiat 2005;162:1227.
43. Ryan ND. Child and adolescent depression: short-term treatment effectiveness and long-term opportunities. Int J Meth Psych Res 2006;12:44-53.
44. Garber J, Horowitz JL. Depression in children. In: Gotlib IH, Hammen CL, eds. Handbook of depression. London: Guilford Press, 2002.
45. Timimi S. Rethinking childhood depression. BMJ 2004;329:1394-6.
46. Science and Environmental Health Network (SEHN). Wingspread conference on the precautionary principle. http://www.sehn.org/wing.html (accessed 18 Jul 2007).
47. Holm S, Harris J. Precautionary principle stifles discovery. Nature 1999;400:398.
48. Resnick DB. The precautionary principle and medical decision making. J Med Philos 2004;29:281-99.
49. March J, Silva S, Benedetto B, TADS Team. The treatment for adolescents with depression study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006;45:1393-1403.
50. Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child 2004;89:1131-2.
51. Anon. Banned depression tablets are still being prescribed to thousands of children. Telegraph 13 Mar 2006. http://www.telegraph.co.uk/ health/main.jhtml?xml=/health/2006/03/13/nkidrugs12.xml (accessed 18 Jul 2008).
52. Anon. How do we tackle the rise in the number of children on antidepressants? Independent 12 Aug 2007. http://news.independent.co.uk/ health/article2851984.ece (accessed 18 Jul 2008).
53. Bannerman L. Parents 'bullying' GPs to get Prozac for children. The Times 17 Nov 2006. http://www.timesonline.co.uk/tol/news/uk/health/ article640047.ece (accessed 18 Jul 2008).
54. Pelton CI. Treatment options may be limited by resources. BMJ 2005;330:418.
55. Sorenson MJ, Mors O, Thomson PH. DSM-IV or ICD-10-DCR diagnoses in child and adolescent psychiatry: does it matter? Eur Child Adolesc Psych 2006;14:335-40.
56. Hazell P. Depression in adolescents. BMJ 2007;335:107.